Hemp Research — Page 146

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

 Drug-Resistant Epilepsy; An Overview on Management and Treatment (2023)

Epilepsy is one of the most prevalent chronic neurological illnesses. Presently, the provision of symptomatic medicine is the treatment method for epilepsy. The majority of patients can attain seizure independence during the first two medication trials. Therefore, pharmaco-resistant individuals are those who cannot get an adequate therapeutic response. However, the range of efficacy, safety, and tolerability, the diversity of seizures and epilepsies, the frequency of comorbidity, and tolerance a

Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition (2023)

GBP1F induced a mild suppression of locomotor activity, ameliorated anxiety and depression-like behavior, did not alter cognitive behavior, and raised serotonin and 5-HIAA concentrations in the hippocampus and striatum. GBP1F also positively enhanced dopamine and vitamin C tissue levels in the striatum. Thus, GBP1F represents a compound with anxiolytic- and antidepressant-like effects though further studies are warranted at the molecular level to focus on the precise mechanism(s) of action.

Zorevunersen in Children and Adolescents with Dravet Syndrome (2026)

The safety profile and initial clinical improvement support the continued development of zorevunersen as a potential disease-modifying treatment for Dravet syndrome. (Supported by Stoke Therapeutics; MONARCH and SWALLOWTAIL ClinicalTrials.gov numbers, NCT04442295 and NCT04740476, respectively; ADMIRAL and LONGWING ISRCTN Registry numbers, ISRCTN99651026 and ISRCTN12811235, respectively.).

Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism (2024)

Autism spectrum disorder (ASD) is characterized by deficits in communication, social interaction, and repetitive and stereotyped behaviors, with no specific drug therapy available. Studies have found that cannabidiol (CBD) can improve hyperactive and cognitive symptoms in children with ASD. However, little is known about the effect of CBD in combination with other medications, such as risperidone (RISP). This study aimed to evaluate the behavioral and biochemical effects of CBD in animals using

Patients with resistant focal epilepsy: what affects the quality of life? (2019)

The aim i s to assess the impact of resistant focal epilepsy on the quality of patients' life. Materials and methods . Prospective, comparative, observational study conducted under conditions of real clinical practice. Inclusion criteria: age over 18 years; the presence of two or more epileptic seizures in history; a long history of treatment-resistant focal epileptic seizures; current AED therapy. Exclusion criteria: history of non-epileptic seizures of any etiology; inability to perform an MRI

Benefits and risks of cannabinoids (2023)

Cannabis is used by an estimated 219 million adults globally (4.3% of the population) with a particularly high prevalence in North America (17.4% of the population).1 The 1961 UN Single Convention on Narcotic Drugs included cannabis with opioids and cocaine as a controlled substance whose use was prohibited, but policies have changed considerably in recent decades. Medical use of cannabis is now permitted in large parts of North and South America, Europe, and Oceania; although, patient access va

The good face of Cannabis sativa: Cannabidiol (2019)

Cannabidiol (CBD) is the second-most common phytocannabinoid found in cannabis plants after tetrahydrocannabinol (THC). Unlike THC, no psychoactive effect has been demonstrated for CBD. Due to its effect on various neurotransmitter systems, it has been tried for the treatment of many physical and psychiatric diseases, considering its neuroprotective and anti-inflammatory properties. In this Editorial, the characteristics of CBD and its place in various psychiatric disorders will be briefly discu

Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline (2025)

These recommendations can be readily implemented clinically and provide a framework for future research. In patients receiving rTMS for a primary psychiatric disorder, assessment and management of co-occurring substance use is complex, requiring greater attention, standardization, and further study.

Genomic Investigation of Infantile and Childhood Epileptic Encephalopathies in Kazakhstan: An Urgent Priority (2021)

<b>Objectives:</b> Infantile and childhood epileptic encephalopathies are a group of severe epilepsies that begin within the first year of life and often portend increased morbidity. Many of them are genetically determined. The medical strategy for their management depends on the genetic cause. There are no facilities for genetic testing of children in Kazakhstan but we have a collection of data with already defined genes responsible for clinical presentations. <b>Methods:</b> We analyzed childr

Demographics and Reported Symptoms Associated With Marijuana Use Among Adolescents and Young Adults (2023)

Purpose Marijuana use has been increasing in the adolescent population. Our objective was to examine the prevalence of marijuana use among a sample of adolescents and young adults, determine an association with risk-taking behaviors, identify reported medical symptoms, and delineate common beliefs about marijuana use. Methods A questionnaire was administered to a sample of patients aged between 12 and 23 years old presenting to the emergency department of Penn State Hershey Medical Center, Hersh

Prescription Practices of Medical Cannabinoids in Children with Cerebral Palsy - A Survey of the Swiss Cerebral Palsy Registry (2021)

Abstract Aim Medical cannabinoids are prescribed to children with cerebral palsy despite limited evidence. We aimed to assess the prescription practices of cannabinoids in children with cerebral palsy with a particular focus on indications and preparations used and how well cannabinoids are tolerated. Furthermore, we investigated how physicians acquire knowledge on cannabinoid medication. Methods We asked physicians with expertise in the care of children with CP on their prescription practices o

MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy (2023)

<b>Background:</b> T-type Ca<sup>2+</sup> channels (Ca<sub>v</sub>3) represent emerging therapeutic targets for a range of neurological disorders, including epilepsy and pain. To aid the development and optimisation of new therapeutics, there is a need to identify novel chemical entities which act at these ion channels. A number of synthetic cannabinoid receptor agonists (SCRAs) have been found to exhibit activity at T-type channels, suggesting that cannabinoids may provide convenient chemical s

Medical cannabis: healthcare professionals' attitudes, perceptions, and behaviors (2021)

Background: The medical marijuana industry and the sociopolitical atmosphere in which it exists have evolved tremendously over the past decade. However, little is known about the healthcare professionals' attitudes, perceptions, and behavior toward patient use of medical marijuana. In order to understand the legitimacy of medical cannabis in the future of palliative care, it is important to understand the beliefs and perceptions of healthcare professionals. Objectives: The purpose of this schola

Evaluation of spontaneous seizure activity, sex-dependent differences, behavioral comorbidities, and alterations in CA1 neuron firing properties in a mouse model of Dravet Syndrome (2021)

Abstract Dravet syndrome (DS) is a rare childhood epilepsy disorder resulting in spontaneous, recurrent seizures (SRS) and behavioral co-morbidities. To facilitate the discovery and development of anti-seizure drugs for DS, the contract site of the NINDS Epilepsy Therapy Screening Program (ETSP) has continued to evaluate a mouse model of DS. Scn1a A1783V/WT mice exhibited increased hyperactivity, thigmotaxis, and deficits in nest-building behavior. Ex-vivo brain slice electrophysiology experimen

Effectiveness of Integrated Medical Treatment for Thunderstorm Aversion: A Case Series of 23 Dogs (2022)

Canine thunderstorm aversion (CTA) is a significant challenge to pets, owners, and veterinarians. The objective of this research was to determine if traditional Chinese veterinary medicine (TCVM) treatment with acupuncture, Chinese herbal medicine, basic desensitization and counterconditioning (DSCC) with a behavior modification drug, could lessen the severity of CTA in dogs. A total of 23 dogs that exhibited behaviors typical of thunderstorm aversion were enrolled in the study. At study start,

Genotype–Phenotype Correlations in SYNGAP1 ‐Related Mental Retardation Type 5 (2024)

Variants in the SYNGAP1 gene leading to decreased SynGAP protein expression are critical for the pathogenesis of mental retardation type 5 (MRD5). This study aims to explore the relationship between SYNGAP1 genotype and clinical phenotype through an expanded sample size, thereby enhancing the understanding of the specific mechanisms underlying MRD5. Data from previously published cases of patients with SYNGAP1 mutations were collected, and the relationship between genotype and clinical phenotype

Phenotypic variability in cases with CACNA1A mutation (2025)

• Instances of intrafamilial variability in CACNA1A variants have been identified, with differing clinical manifestations exhibited by affected family members. • Incomplete penetrance is a phenomenon that may occur, as neurodevelopmental or neuropsychiatric findings are not exhibited by some patients with CACNA1A variants.